The Juniper Team
Why a fund investing in non-pharma biotech approaches bioethics differently, and the framework we use to practice it.
Why a fund investing in non-pharma biotech approaches bioethics differently, and the framework we use to practice it.
Why the next generation of fund-returners will be category kings, and why biology is where they're being built
Why the next generation of fund-returners will be category kings, and why biology is where they're being built
The Methane Economy
The Methane Economy
From evolutionary constraint to competitive advantage.
From evolutionary constraint to competitive advantage.
.png)
Lessons from biotech’s first breakout moment.
Lessons from biotech’s first breakout moment.
.png)
Our bioindustrial advantage is vulnerable. Here’s how we secure it.
Our bioindustrial advantage is vulnerable. Here’s how we secure it.
.png)
How biotech in space will improve life on Earth.
How biotech in space will improve life on Earth.
.jpg)
How to diversify your capital stack and reduce dilution.
How to diversify your capital stack and reduce dilution.
A peek behind the curtain.
A peek behind the curtain.
.jpg)
